Ann: Annual Report to Shareholders, page-60

That's the great thing about Rex-L for CLBP, pain reduction, opioid sparing, most likely surgery saving - most likely cost saving over the long term taking into account opportunity costs. Game changer! Hope the FDA finds a way to approve it asap (likewise for CHF) and not get overly hung up on the primary endpoints we chose for said trials. Just think it is common sense to approve on basis for what we were able to show (even if opioid sparing effect not chosen as primary ...). But also know the approval process is a little more complicated to say the least. Hoping MSB/FDA will find a path forward for an accelerated approval pathway for our Rex-L therapies (and Rem-L too). Just what the doctor, parents and society at large ordered!